Tafecta (Vemlidy) is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
DOSAGE AND ADMINISTRATION
1. Testing: Prior to initiation of Tafecta, test patients for HIV infection. Tafecta alone should not be used in patients with HIV infection. Assess serum creatinine, serum phosphorous, estimated creatinine clearance, urine glucose, and urine protein before initiating Tafecta and during therapy in all patients as clinically appropriate.
2. Recommended dosage: 25 mg (one tablet) taken orally once daily with food.
3. Renal Impairment: Tafecta is not recommended in patients with estimated creatinine clearance below 15 mL per minute
4. Hepatic Impairment: Tafecta is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.